Tango Therapeutics, INC Form 4 insider transactions

Alexis Borisy, a Director at Tango Therapeutics, has acquired 6,250 restricted stock units and 37,500 stock options, signaling continued confidence in the company's future.

Douglas Barry, General Counsel of Tango Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Daniella Beckman, CFO of Tango Therapeutics, sold shares of common stock on February 4th and 5th, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Adam Crystal, an executive at Tango Therapeutics, sold shares of common stock on February 4th and 5th, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Tango Therapeutics CEO Barbara Weber sold shares of common stock on February 4th and 5th, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Daniella Beckman, CFO of Tango Therapeutics, reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Adam Crystal, a key executive at Tango Therapeutics, reports the acquisition of restricted stock units and stock options, signaling potential future ownership in the company.

CEO Barbara Weber reports the acquisition of restricted stock units and stock options in Tango Therapeutics, Inc.

Douglas Barry, General Counsel of Tango Therapeutics, reports the acquisition of stock options and restricted stock units in the company.

Director Mace Rothenberg of Tango Therapeutics has acquired 20,000 shares of common stock through open market purchases.

EcoR1 Capital, LLC, along with related entities, reports the sale of Tango Therapeutics, Inc. (TNGX) common stock across multiple transactions.

Boxer Capital Management, a significant shareholder in Tango Therapeutics, sold 3,080,000 shares of common stock at an average price of $3.14 per share.

Boxer Capital Management, a significant shareholder in Tango Therapeutics, sold 633,000 shares of common stock at an average price of $6.87.

Boxer Capital Management, a significant shareholder of Tango Therapeutics, recently sold a portion of its holdings in two transactions.

Third Rock Ventures IV, L.P. reports the sale of 67,400 shares of Tango Therapeutics, Inc. at a weighted average price of $10.5305 per share.

Third Rock Ventures IV, L.P. disposed of 75,000 shares of Tango Therapeutics (TNGX) at an average price of $11.5618 on September 5, 2024.

Aaron I. Davis, reported as potentially part of a group owning over 10% of Tango Therapeutics, acquired stock options for 65,000 shares as compensation for consulting services.

Third Rock Ventures IV, L.P. reports the sale of 175,000 shares of Tango Therapeutics, Inc. at an average price of $11.5983 per share.

Third Rock Ventures IV, L.P., a significant shareholder of Tango Therapeutics, Inc., disposed of 25,000 shares of common stock at an average price of $11.5466 on August 27, 2024.

Third Rock Ventures IV, L.P. sold 285,000 shares of Tango Therapeutics (TNGX) common stock in two transactions during August 2024.

Third Rock Ventures IV, L.P. sold a total of 235,000 shares of Tango Therapeutics (TNGX) between July 30, 2024, and August 1, 2024.

Third Rock Ventures IV, L.P., a significant shareholder of Tango Therapeutics, Inc. (TNGX), sold 50,000 shares of common stock at an average price of $9.839 per share on July 26, 2024.

Third Rock Ventures IV, L.P. sold shares of Tango Therapeutics (TNGX) in multiple transactions on July 24 and July 25, 2024.

Third Rock Ventures IV, L.P. sold shares of Tango Therapeutics (TNGX) on July 22 and 23, 2024, reducing its holdings.

Third Rock Ventures IV, L.P. sold 191,490 shares of Tango Therapeutics (TNGX) common stock at a price of $9.8098 per share on July 18, 2024.

Third Rock Ventures IV, L.P. sold 550,171 shares of Tango Therapeutics, Inc. at a weighted average price of $9.7903 on July 17, 2024.

MVA Investors, LLC, a significant shareholder in Tango Therapeutics, Inc., has sold a portion of its holdings in a series of transactions between June 28, 2024, and July 2, 2024.

MVA Investors, LLC, along with Aaron I. Davis, reports the sale of Tango Therapeutics, Inc. common stock.

Director Malte Peters acquired shares and options in Tango Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Director Mace Rothenberg acquired shares and options in Tango Therapeutics, Inc. on June 5, 2024.